New hope for tough colon cancer: combo therapy tested in 20 patients

NCT ID NCT07150247

First seen Nov 01, 2025 · Last updated Jun 12, 2026 · Updated 33 times

Summary

This study tests whether a combination of two experimental drugs (iparomlimab and tuvonralimab) plus standard chemotherapy and a targeted therapy can shrink tumors in adults with a specific type of advanced colorectal cancer (BRAF V600E mutation). About 20 people whose cancer has worsened after at least one prior treatment will receive the drug combo every two weeks. The goal is to see if the treatment is safe and works better than past results.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BRAF V600 COLORECTAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Sun Yat-sen University Cancer Center

    RECRUITING

    Guangzhou, Guangdong, 510060, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.